Soleno Therapeutics (NASDAQ:SLNO) shares fell nearly 10% premarket on Thursday after the company proposed an offering of $200 million of shares of its common stock.
In addition, the biopharmaceutical company intends to grant the underwriters a 30-day option to purchase up